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Letter to the editor
Spain has been one the most affected countries by the 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), the causative agent of coronavirus disease 2019 
(COVID-19) pandemic [1, 2]. Patients with chronic lym-
phocytic leukemia (CLL) could be at risk of more severe 
COVID-19 clinical forms [3] since they often carry 
immune perturbations aggravated by treatments used 
for the disease itself [4]. Two major series on patients 
with COVID-19 and CLL encompassing different coun-
tries and health systems reported heterogeneous factors 
related to the outcome [5, 6]. Herein, we are presenting 
the largest series of CLL patients with proved COVID-19 
from a single country and Health system.
We identified 165 patients with CLL and COVID-19 
across 40 Spanish centers (Additional file 1: Table S1 and 
S2) between March 1, 2020 and May 31, 2020. In sum-
mary, at the time of infection median age was 73 years, 
27% were younger than 65, and 40% had comorbidi-
ties (CIRS ≥ 6). Eighty-five patients (52%) were in watch 
& wait (W&W), 34 (21%) had been previously treated, 
whereas 46 patients (28%) were currently on CLL treat-
ment, mainly with BTK inhibitors (BTKi) (n = 34) and 
venetoclax (n = 7). Increased CRP (> 0.3  mg/dL) was 
detected in 27.8%, increased D-dimer (> 500  mg/mL) in 
70%, ferritin > 400  mg/mL in 74%, and elevated IL-6 in 
88% of patients in whom it was assessed. Among these 
inflammatory parameters, ferritin and D-dimer were sig-
nificantly lower in patients receiving BTKi at the time of 
COVID-19 compared to the others (Additional file 1: Fig. 
S1). 92% of the patients required hospital admission, with 
31% requiring intensive management.
Regarding survival, 45 deaths (27%) were observed, all 
of them due to SARS-CoV-2 infection. The case fatality 
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rate (CFR) for admitted patients was 33.6% and the OS 
estimates of the entire cohort at 28  days was 74.1%. In 
the univariate analysis, age, CIRS ≥ 6, Binet stage B-C, 
hemoglobin < 10  g/dL, lymphocytosis (≥ 30 × 109/L), 
CRP, and D-dimer levels were associated with OS. At the 
multivariate analysis, age (HR = 1.36, [95% CI 1–1.86]), 
lymphocytosis (HR = 1.96, [95% CI 1.05–3.63]), and 
D-dimer (HR = 4.35, [95% CI 1.53–12.3]) maintained its 
independent statistical significance (Fig.  1 & Additional 
file 1: Table S3). Patients on W&W presented similar OS 
than patients receiving an active CLL-directed therapy. 
Notably, treatment with BTKi (n = 34) did not influence 
mortality of the infection in comparison with patients on 
W&W (HR: 1.1 [CI 95% 0.5–2.42]; Fig. 1d).
Mortality rate by segments of age was contrasted with 
937 patients admitted for COVID-19 at University Hos-
pital Vall d’Hebron, excluding patients with hemato-
logic malignancies, solid tumors, or with other causes 
of immunosuppression. Overall, mortality rates were 
higher in CLL patients (adjusted OR = 1.74 [95% CI 
1.14–2.65], p = 0.01). The major difference between both 
cohorts was observed in the higher mortality for CLL 
patients < 60  years (16.7% vs 0.7%, p < 0.001). Of note, 
three out of the four young CLL patients that died were 
untreated and lack comorbidities, suggesting a negative 
effect of CLL in those patients. Finally, mortality was sig-
nificantly higher compared to the mortality rates by age 
reported by the Spanish Ministry of Health up to May 
2020 (adjusted OR = 3.91 [95% CI 2.70–5.66], p < 0.001) 
(Fig. 2 and Additional file 1: Table S4).
The inferior survival observed in patients with CLL 
and COVID-19 in our series seems to be similar to the 
data reported in other series of patients with hematologic 
malignancies, pointing to a patient population more vul-
nerable to COVID-19 infection [7].
In summary, in our series mortality rate was 27%, 
with a CFR for admitted patients of 33.6%, resembling 
the ones reported by Mato et  al. [5] and by the ERIC/
CLL Campus series [6]. In contrast to the observations 
reported by the ERIC/CLL Campus series, and in agree-
ment with Mato et  al. [5], age and comorbidities were 
strongly related to mortality. Importantly, and as opposed 
to the two former mentioned series [5, 6], lymphocyto-
sis was associated with OS, suggesting that a more active 
Fig. 1 Overall survival curves according to (a) age, (b) Lymphocyte count, (c) D‑dimer levels, and (d) BTKi treatment
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CLL disease at the time of infection could increase the 
vulnerability to COVID-19. The inflammatory param-
eters analyzed in our series corelated with COVID-19 
outcome. Thus, increased CRP and D-dimer predicted 
for a shorter survival, the latter maintaining its adverse 
prognostic impact in the multivariate analysis. Finally, in 
our series and in agreement with Mato et al. [5] patients 
receiving BTKi at the time of COVID-19 presented simi-
lar outcome as patients never treated and, accordingly 
exhibit lower levels of ferritin and D-dimer, which could 
be in part explained by the suggested protective role of 
BTKi against SARS-CoV-2 infection severity due to its 
immune-modulator effect [8–10].
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